With a population one-tenth the size of the US, Canada often sits in the shadow of its neighbour to the south. But when it comes to the quality of its life sciences research and biotech innovation, it stands shoulder-to-shoulder to the US. Life sciences stakeholders have been slowly taking more notice.
Versant Ventures is a global biopharma venture capital firm that has two of its six offices located in Canada and dedicates 20% of its US $4.2bn fund to Canadian early-stage biotech companies